Ministry of Public Health reveals 105 years infected with covids, never vaccinated, survived because LAAB aims to increase use in cancer patients
Today (18 September) Dr. Opas Karnkawinpong, MD. Director-General of the Department of Disease Control The Ministry of Public Health (MOPH) revealed that Thailand has provided a ready-made immune system (Long Acting Antibody (LAAB)) to the people who are in need, counting as an upgrade to enhance their immunity against COVID-19 to take care of and protect the health of the people. especially for patients with low immunity The body is unable to build immunity by vaccination. 608 risk groups, such as chronic renal failure patients undergoing dialysis. Organ or bone marrow transplanters receiving immunosuppressant medications immune compromised This group, if infected, may be at risk of severe illness. or have a high chance of dying
“Most recently, in early September 2022, a COVID-19 patient was found aged 105 years and had never been vaccinated against COVID-19. Was admitted to a hospital (hospital) on September 3, 2022 with high fever, sputum, low blood oxygen. and later had a bacterial lung infection. This patient received antiretroviral therapy on the first day. But due to old age, the risk of death Doctors therefore consider giving patients ready-made immunotherapy (LAAB) on September 4, 2022, along with antibiotics. which since September 10, 2022, the patient’s symptoms gradually better in order The symptoms of lung infection decreased, fever decreased, blood oxygen returned to normal. And the patient can go home on September 14, 2022, the total duration of treatment is less than 2 weeks. The immunization package, or LAAB, should be effective in treating elderly patients in at-risk groups who do not have immunity. as soon as possible before the infectionsaid Dr. Opas.
Director-General of the Department of Disease Control Mentioned that the LAAB immune system works to boost immunity in people who are less responsive to vaccines than the general population. When injected into the body, the body will build immunity to COVID-19. high immediately after injection make a lot of benefits To reduce the risk of death in such patients. In foreign countries, LAAB has been registered to use immunosuppressants in the treatment of COVID-19 patients. Vulnerable groups at risk of death as well, such as the United States, Japan, etc.
“In Thailand, LAAB immunosuppressants are imported and the first injection is given to chronic renal failure patients undergoing dialysis. at Bamrasnaradura Institute on July 27, 2022 and sent to various provinces Nationwide since August 1, 2022, target groups in the early stages of chronic renal failure patients who need kidney replacement therapy (dialysis) who have received organ transplants. bone marrow transplant patients They can consult a doctor for consideration in enhancing their immunity against COVID-19 with LAAB, or they can contact the hospital for injections,” said Opas. At the same time, the Ministry of Public Health has given policies to the Provincial Public Health Office (PSU) in all provinces across the country. Survey the number of eligible patients in all hospitals under In order for the target group to receive complete immunity from LAAB, the Ministry of Health is also considering adding target groups that need to be immunized, such as cancer patients undergoing chemotherapy and radiation therapy, organ transplant patients requiring high-dose immunosuppressant drugs, rheumatic patients requiring immunosuppressant therapy and other immunocompromised patients